Alimlieva-500 Injection 1's belongs to the group of medicines called folate analogue metabolic inhibitors used alone or in combination with other anti-cancer medicines to treat non-small cell lung cancer and malignant pleural mesothelioma (cancer affecting the lining of the lung).

Alimlieva-500 Injection 1's contains Pemetrexed, which works by blocking the action of substances that may help the cancer cells multiply.

In some cases, Alimlieva-500 Injection 1's may cause side effects such as diarrhoea, tiredness, nausea, vomiting, and loss of appetite. Most of these side effects may not require medical attention and resolve gradually over time. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen.

Do not use Alimlieva-500 Injection 1's if you are pregnant or breastfeeding. Alimlieva-500 Injection 1's is not recommended for children below 18 years. Women and men should use effective contraception during treatment with Alimlieva-500 Injection 1's and for 6 and 3 months afterwards. Inform your doctor about your health condition and medications to rule out any side effects/interactions.

Alimlieva-500 Injection 1's is used in the treatment of Non-small cell lung cancer and malignant pleural mesothelioma. The detailed uses of Alimlieva-500 Injection 1's are as follows:

• Non-Small Cell Lung Cancer (NSCLC): Alimlieva-500 Injection 1's is used alone or in combination with other agents for advanced or metastatic NSCLC, especially in patients who are not candidates for surgery.
• Malignant Pleural Mesothelioma: Alimlieva-500 Injection 1's is often combined with cisplatin to treat this aggressive cancer affecting the lining of the lungs.

• Follow your doctor’s instructions on the dosage and timing of this medication.
• Alimlieva-500 Injection 1's will be administered by a nurse or doctor.
• Do not self-administer.

Alimlieva-500 Injection 1's contains Pemetrexed, which belongs to the group of medicines called anti-folate anti-neoplastic agents indicated in the treatment of malignant pleural mesothelioma and non-small cell lung cancer in initial treatment in combination with cisplatin, as maintenance treatment of patients whose disease has not progressed after four cycles of platinum-based first-line chemotherapy and after prior chemotherapy as a single agent. Alimlieva-500 Injection 1's treats cancer by blocking the action of substances that may help the cancer cells multiply.

Do not use Alimlieva-500 Injection 1's if you are allergic to any of its components, pregnant or breastfeeding, or if you have taken or plan to receive yellow fever vaccination. Inform the doctor if you have/had heart disease, kidney problems, have had or are going to have radiation therapy, or have accumulation of fluid around the lungs. Seek immediate medical attention if you experience symptoms of fever or infection; pain, sores, redness or swelling in the mouth; chest pain or a fast heartbeat; allergic reaction (skin rash, burning/prickling sensation, or fever); Stevens-Johnson Syndrome or toxic epidermal necrolysis (severe rash, itching, or blistering); low haemoglobin levels (tiredness, feeling faint, paleness, or becoming easily breathless); low platelet count (bleeding from gums/nose/mouth, bleeding that does not stop, unexpected bruising, reddish or pinkish urine); or blood clot in the blood vessels of the lungs (sudden breathlessness, cough with bloody sputum or intense chest pain).